Substance Withdrawal Syndrome Clinical Trial
Official title:
Does Abstinence From E-cigarettes Produce Withdrawal Symptoms?
Verified date | November 2018 |
Source | University of Vermont |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to see whether adults who use e-cigarettes every day experience symptoms of nicotine withdrawal when they stop using e-cigarettes for 6 days.
Status | Completed |
Enrollment | 147 |
Est. completion date | October 31, 2018 |
Est. primary completion date | October 31, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - 18 years or older - Able to read and understand verbal English fluently - US citizen or resident alien - Primarily uses e-cigarette product types of refillable tanks or modified devices - Uses nicotine-containing e-liquid - Has baseline urinary cotinine concentration of > 100 ng/ml - Has used e-cigarettes daily for the last 2 months - Has a home or cell phone - Agrees to abstain from tobacco, marijuana and other illegal drugs during study Exclusion Criteria: - Smoked > 5 tobacco cigarettes in the last month - Used non-cigarette nicotine, tobacco or quit smoking products on >5 days in the past month - Use of cannabis (either marijuana or synthetic cannabis) > 5 times in the past month or positive test for cannabis use at screening - Current (last 6 months) Generalized Anxiety Disorder, Major Depressive Disorder, Attention Deficit Hyperactivity Disorder or moderate/severe Substance Abuse Disorder - Multiple legal, social health, work or school problems in the past month due to alcohol or drug use - Pregnant or breastfeeding - Previously a participant in the current study - Use of prescribed or non-prescribed psychoactive medication > 5 times in the past month - Expired carbon monoxide level > 8ppm |
Country | Name | City | State |
---|---|---|---|
United States | Battelle Memorial Institute | Baltimore | Maryland |
United States | University of Vermont | Burlington | Vermont |
Lead Sponsor | Collaborator |
---|---|
University of Vermont | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total score on the Minnesota Nicotine Withdrawal Scale (MNWS) | The investigators will compare the mean score across participants for the entire 6-day abstinence vs. use conditions. | 6 days | |
Secondary | Individual items on the Minnesota Nicotine Withdrawal Scale (MNWS) | The investigators will use the mean score for each of the 16 symptoms across participants during abstinence and use conditions. | 6 days | |
Secondary | Questionnaire of E-cigarette Urges (brief) | This is a revision of the brief version Questionnaire of Smoking Urges that asks about urges for e-cigarettes rather than tobacco cigarettes. | 6 days | |
Secondary | Questionnaire of Smoking Urges- brief version | This 2-item scale asks about intensity and frequency of urges. | 6 days | |
Secondary | Heart rate | Measured for 30 sec after sitting for 15 minutes | 6 days | |
Secondary | E-cigarette Purchase Task | This is a modification of the Cigarette Purchase Task that asks how much users would expend to obtain their usual amount of e-liquids to use. | 6 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00114439 -
Lithium Cannabis Withdrawal Study
|
Phase 2 | |
Completed |
NCT00980044 -
Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal
|
Phase 2/Phase 3 | |
Completed |
NCT02643355 -
Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED
|
N/A | |
Completed |
NCT02782156 -
Process Evaluation Standardised Nurse-led Approach for Risk Screening and Decrease of Alcohol Withdrawal in ENT
|
N/A | |
Recruiting |
NCT00792415 -
Validation of a Pediatric-Specific Abstinence Syndrome Assessment Tool
|
N/A | |
Completed |
NCT02431728 -
The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program
|
Phase 1/Phase 2 | |
Completed |
NCT00695864 -
Effect of Ondansetron for Withdrawal Symptoms
|
N/A | |
Active, not recruiting |
NCT02951793 -
Abuse and Addiction in ICU
|
||
Completed |
NCT02108626 -
Electronic Cigarettes in Daily Dependent Smokers
|
Phase 4 | |
Recruiting |
NCT04917185 -
EA for PAAS: A pRCT
|
N/A | |
Completed |
NCT02801357 -
Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction
|
Phase 1 | |
Completed |
NCT01362959 -
Nicotine Replacement Therapy in the Intensive Care Unit
|
Phase 4 | |
Completed |
NCT00992979 -
Therapeutic Massage to Manage Withdrawal Related Anxiety
|
Phase 2 | |
Completed |
NCT00900900 -
The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers
|
Phase 2 | |
Completed |
NCT02318290 -
Opioids Withdrawal Syndrome in Critically Ill Patients: a Multicenter Prospective Cohort Study
|
N/A | |
Completed |
NCT00032968 -
Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1
|
Phase 3 | |
Completed |
NCT03374722 -
Opioid Withdrawal Symptoms in Critically Ill Patients
|
||
Completed |
NCT03435614 -
Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults
|
||
Completed |
NCT00570219 -
The Effect of Valproate on Benzodiazepine Withdrawal Severity
|
N/A | |
Completed |
NCT00367874 -
Treatment of Polydrug-Using Opiate Dependents During Withdrawal
|
Phase 4 |